Media

For media enquiries about any aspect of the work of the PMCPA please contact the Press Office  Direct: 02077478884 Mobile: 07920863650 ebutton@pmcpa.org.uk                                     Sign up for eAlerts at the top of the page   Follow us on Twitter @PMCPAUK                 FOR THE LATEST PRESS RELEASES AND TWEETS SCROLL DOWN                           

The PMCPA publishes certain Sanctions (advertisements, public reprimands and corrective statements) Press Releases, Case Reports and Code of Practice Reviews

In each case where a breach of the ABPI Code of Practice for the Pharmaceutical Industry is ruled, the company concerned must give an undertaking that the practice in question has ceased forthwith and that all possible steps have been taken to avoid a similar breach in the future.  The undertaking must be accompanied by details of the action taken to implement the ruling.  At the conclusion of a case, a detailed case report is also published.
 
Additional sanctions can also be imposed. These include:
  • the carrying out by the PMCPA of an audit of a company’s procedures to comply with the Code. This can also be followed by a requirement that promotional material be submitted to the PMCPA for pre-vetting for a specified period
  • requiring the company to take steps to recover items from those to whom they have been given
  • requiring the company to issue a corrective statement
  • a public reprimand
  • suspension or expulsion from membership of the ABPI.

Where companies are ruled in breach of Clause 2 of the Code, and/or are required to issue a corrective statement and/or are the subject of a public reprimand, the PMCPA advertises brief details of the cases in the medical, nursing and pharmaceutical press, the advertisements are also published on this website. 

Case Reports (access Case Reports here)

When cases are considered under the Code they will first appear on this site as an ongoing case, limited information is provided which includes a brief summary and the status of the case.  At the conclusion of any case, a case report is published summarising the details of the case, these appear as completed cases on this site.  The transparency of cases is vital. Case reports are published for all cases which are within the scope of and considered under the Code, whether they are found to have breached the Code or not.  

As mentioned above, in some cases a company may be required to issue a corrective statement or may be the subject of a public reprimand or advertisements in the medical and pharmaceutical press. 

Code of Practice Review (access Code of Practice Reviews here)

The Code of Practice Review is published quarterly by the PMCPA. It includes the case reports of all cases completed within the previous three months, new advice that has been issued on the Code and an editorial relating to current matters of interest. 

News

all news
  • Otsuka Pharmaceuticals Europe Ltd and Indivior UK limited have been named in advertisements for breaches of the ABPI Code. In addition Otsuka Pharmaceuticals Europe Ltd and AstraZeneca have been publicly reprimanded.

    25 June 2020

    read more
  • LAUNCH OF ABPI CONSULTATION ON PROPOSALS FOR THE ABPI CODE OF PRACTICE 2021

    19 June 2020

    read more
  • COVID-19 Updates on PMCPA staffing, Seminars and Examination extensions.

    18 March 2020

    read more
  • Daiichi-Sankyo, GW Pharmaceuticals, Bayer plc, Proveca Ltd, Otsuka UK and Otsuka Europe named in advertisements for breaches of the ABPI Code of Practice

    27 July 2019

    read more
  • MHRA Guidance Updates - prescribing information for centrally approved products in the event of the UK leaving the EU with no deal

    10 April 2019

    read more
  • Sunovion and Shield named in advertisements for breach of ABPI Code of Practice

    17 December 2018

    read more